{"id":85219,"date":"2026-04-27T19:32:20","date_gmt":"2026-04-27T19:32:20","guid":{"rendered":"https:\/\/diyhaven858.wasmer.app\/index.php\/intellia-says-crispr-based-treatment-for-rare-disease-reduced-swelling-attacks-in-pivotal-trial\/"},"modified":"2026-04-27T19:32:20","modified_gmt":"2026-04-27T19:32:20","slug":"intellia-says-crispr-based-treatment-for-rare-disease-reduced-swelling-attacks-in-pivotal-trial","status":"publish","type":"post","link":"https:\/\/diyhaven858.wasmer.app\/index.php\/intellia-says-crispr-based-treatment-for-rare-disease-reduced-swelling-attacks-in-pivotal-trial\/","title":{"rendered":"Intellia says CRISPR-based treatment for rare disease reduced swelling attacks in pivotal trial"},"content":{"rendered":"<p> <br \/>\n<\/p>\n<div>\n<p>Intellia Therapeutics said Monday that a single dose of its gene editing treatment dramatically reduced swelling attacks in patients with a rare genetic disorder in a Phase 3 trial, setting up a potential approval.<\/p>\n<p>The therapy, known as lonvo-z, would be the second approved CRISPR-based medicine, after Vertex Pharmaceutical\u2019s sickle cell treatment Casgevy. Intellia has already initiated a rolling submission with the agency. It would be the first in vivo treatment, meaning it edits patients\u2019 DNA directly in the body.\u00a0<\/p>\n<p>In the 80-patient study, volunteers with hereditary angioedema (HAE) who received lonvo-z saw their attack rates drop 87%, relative to placebo. Just over 60% were entirely attack-free over the period, compared to 11% for the placebo patients.<\/p>\n<div class=\"restricted-content-breaker article\" aria-labelledby=\"restricted-story-heading\" aria-describedby=\"restricted-story-description\" checked=\"false\">\n<div class=\"restricted-content-breaker-bar\">\n<p class=\"restricted-text\">STAT+ Exclusive Story<\/p>\n<p class=\"restricted-login\">Already have an account? Log in<\/p>\n<\/p><\/div>\n<p>\t\t\t<img decoding=\"async\" class=\"restricted-content-breaker-bg\" src=\"https:\/\/www.statnews.com\/wp-content\/themes\/stat\/images\/stat-plus-breaker-bg.png\" alt=\"STAT+\"\/><\/p>\n<div class=\"restricted-content-breaker-wrapper\">\n\t\t\t\t<span class=\"stat-paywall-archive\"><\/p>\n<p>\t\t\t\t\t\t<img decoding=\"async\" class=\"stat-plus-logo\" src=\"https:\/\/www.statnews.com\/wp-content\/themes\/stat\/images\/stat-plus-logo-white.svg\" alt=\"STAT+\"\/><\/p>\n<p>\t\t\t\t<\/span><\/p>\n<h2 id=\"restricted-story-heading\">This article is exclusive to STAT+ subscribers<\/h2>\n<h3 id=\"restricted-story-description\">Unlock this article \u2014 plus daily coverage and analysis of the biotech sector \u2014 by subscribing to STAT+.<\/h3>\n<p class=\"restricted-content-breaker-wrapper-cta mobile\">Already have an account? Log in<\/p>\n<div class=\"restricted-content-breaker-cards\">\n<div class=\"slider-container\" aria-label=\"Subscription plan toggle\">\n\t\t\t\t\t\t<button type=\"button\" class=\"individual\" aria-pressed=\"false\">Individual plans<\/button><\/p>\n<p>\t\t\t\t\t\t<button type=\"button\" class=\"group\" aria-pressed=\"false\">Group plans<\/button>\n\t\t\t\t\t<\/div>\n<\/p><\/div>\n<p>\t\t\t\tView All Plans\n\t\t\t<\/p><\/div>\n<\/p><\/div>\n<div class=\"restricted-message-breaker\">\n<div class=\"restricted-content-wrapper\">\n<div class=\"restricted-content-message\">\n<p class=\"restricted-content-text\">\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n<p>\t\t\t\t\tSubscribe\n\t\t\t\t\t\t\t\t\t<\/p><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<p><br \/>\n<br \/><<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Intellia Therapeutics said Monday that a single dose of its gene editing treatment dramatically reduced swelling attacks in patients with a rare genetic disorder in a Phase 3 trial, setting up a potential approval. The therapy, known as lonvo-z, would be the second approved CRISPR-based medicine, after Vertex Pharmaceutical\u2019s sickle cell treatment Casgevy. Intellia has [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":85220,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_daextam_enable_autolinks":"","jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[2],"tags":[],"class_list":["post-85219","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/diyhaven858.wasmer.app\/wp-content\/uploads\/2026\/04\/Intellia-Therapeutics-headquarters-in-Cambridge-Mass-1024x576.jpg","jetpack_sharing_enabled":true,"jetpack-related-posts":[],"_links":{"self":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/posts\/85219","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/comments?post=85219"}],"version-history":[{"count":0,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/posts\/85219\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/media\/85220"}],"wp:attachment":[{"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/media?parent=85219"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/categories?post=85219"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/diyhaven858.wasmer.app\/index.php\/wp-json\/wp\/v2\/tags?post=85219"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}